<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) is the principal risk factor for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>BE patients currently undergo periodic endoscopic surveillance with tissue sampling and histopathologic assessment for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>They frequently are prescribed <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> to pharmacologically suppress gastric acid that is the cause of BE </plain></SENT>
<SENT sid="3" pm="."><plain>These standard endoscopic and pharmacologic approaches for managing BE are crude at best </plain></SENT>
<SENT sid="4" pm="."><plain>Identification of novel tissue biomarkers within BE may allow for more accurate endoscopic risk stratification and provide potential targets for chemoprevention </plain></SENT>
</text></document>